The trend towards lower baseline IL-6 levels in our subgroup of patients with a history of immune-mediated disease further supports the association between irAEs and low post-ICI IL-6 levels, while also suggesting the involvement of an IL-6-independent pathway in the pathogenesis of these pre-existing diseases, such as the well-established IL-17 pathway in psoriasis. This evidence concerns the gene IL17A and psoriasis.